Cell Signaling Technology has presented a specific HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors.
The company has introduced this product with the recent need for HER3 in HER2 transformation of normal cells in at least a subset of cancers.
HER3 avoids well known background issues when using mouse antibodies for IHC in mouse xenograft models in cancer research.
The antibody has shown no cross-reactivity with other family members, including EGFR, HER2/ErbB2 and HER4/ErbB4 in extensive testing.
HER3 will be initially used in immunohistochemistry (IHC). The company's HER3/ErbB3 XP Rabbit mAb has been validated for IHC as well as Western Blot, Immunofluorescence (IF) and Flow Cytometry.
Cancer Research Group of the company is concentrating on making it simple to understand the signaling networks that cause various cancers.
The study of the cancer proteome has identified EML4-ALK fusion in a subset of patients with breast, colon and non-small cell lung cancer (NSCLC) using the proteomic technologies.
Patents have been issued for EML4-ALK in NSCLC that span from research through diagnosis and therapy.
